Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
"Aurora Cannabis Inc." Q1 Fiscal 2027 Earnings Call - International Medical Revenue Surges 17% as Global Strategy Offsets Canadian Headwinds
Aurora Cannabis is executing a disciplined pivot that is already reshaping its revenue mix. A 30% cut in Canadian federal reimbursement rates created expected near-term pressure, but the company’s str...
- International medical cannabis net revenue climbed 17% to CAD 43 million, now representing 64% of total net revenue, up from 50% a year ago.
- Consolidated adjusted gross margin held at 58%, landing at the high end of full-year guidance despite expected Canadian reimbursement cuts.
- The Safari Flower Company acquisition is already accretive to adjusted EBITDA and delivers critical EU GMP-certified indoor cultivation capacity.
- +9 more takeaways
"DHL Group" Q2 2026 Earnings Call - Guidance Raised as Express Industrial Pivot Drives Broad Margin Expansion
DHL Group did not just ride the recovery cycle. It engineered it. Revenue accelerated 13% year-over-year while EBIT jumped 30%, a flow-through that leaves management comfortable enough to lift full-ye...
- Group revenue accelerated 13% year-over-year, with EBIT surging 30% as volume growth flowed through the bottom line.
- Management raised full-year guidance, now projecting EBIT to exceed €6.5 billion, backed by broad-based demand recovery.
- The share buyback program extends through 2027 and expands to €6.5 billion in cumulative value, signaling strong confidence in cash generation.
- +8 more takeaways
Gilead Sciences Q2 2026 Earnings Call - Base Business Surges 10% as HIV PrEP Crosses $1B and M&A Charges Compress Reported Margins
Gilead delivered its strongest second quarter growth in three years, with base business sales climbing 10 percent year over year to $7.6 billion. The engine is unmistakably virology. HIV treatment rem...
- Base business sales surged 10 percent year over year to $7.6 billion, with sequential growth of 12 percent driven by strength across HIV, oncology, and liver disease.
- HIV franchise guidance raised to 9 to 10 percent full year growth, up from 8 percent, as Biktarvy maintains treatment leadership and PrEP run rates accelerate.
- PrEP sales exceeded $1 billion quarterly for the first time, establishing a $4 billion annual run rate and validating Gilead's long acting prevention strategy.
- +7 more takeaways
"LeMaitre Vascular" Q2 2026 Earnings Call - Artegraft Growth Offsets Supply and Currency Headwinds
LeMaitre Vascular delivered a quarter defined by structural acceleration and familiar execution friction. Artegraft continues to rewrite the company’s growth curve, jumping 34% and now representing ov...
- Q2 organic revenue growth came in at 10%, driven by 7% pricing and 3% unit growth, though excluding a catheter recall hangover, underlying growth accelerated to 12%.
- Artegraft remains the primary growth engine, surging 34% to capture 21% of total sales, with full-year 2026 sales now forecast at $11 million versus $4 million in 2025.
- The company missed Q2 sales guidance by $1.1 million, split evenly across currency headwinds, Middle East export delays, and cardiac allograft supply bottlenecks.
- +9 more takeaways
"ACADIA Pharmaceuticals" Q2 2026 Earnings Call - DAYBUE STIX Uptake Drives Raised Guidance as Remlifanserin Readout Looms
ACADIA delivered a quarter defined by commercial momentum and pipeline precision. Total revenue climbed 17% to $308 million, anchored by a 30% surge in DAYBUE sales as the new STIX formulation capture...
- Total Q2 revenue reached $308 million, up 17% year-over-year on an adjusted basis, driven by strong volume across both core brands.
- DAYBUE net sales surged 30% to $125 million, fueled by rapid adoption of the STIX formulation, which now accounts for roughly 40% of the U.S. patient base.
- Management raised full-year 2026 DAYBUE guidance to $480 million–$510 million, citing accelerating demand and successful expansion beyond Centers of Excellence.
- +7 more takeaways
Alight Q2 2026 Earnings Call - Management Targets 2028 for Turnaround While Preserving Capital Flexibility
Alight delivered a Q2 2026 print that highlights a familiar services sector friction: commercial improvements take time to hit the bottom line. Revenue fell 3% to $511 million, dragged down by a 4.3% ...
- Q2 revenue landed at $511 million, down 3% year-over-year, with recurring income slipping 4.3% as the company absorbs the lag from prior commercial execution.
- Adjusted EBITDA reached $92 million on an 18% margin, beating street estimates thanks to unexpected project revenue strength and higher operating volumes.
- Full-year 2026 revenue guidance sits between $2.078 billion and $2.098 billion, with adjusted EBITDA projected at $400 million to $415 million.
- +7 more takeaways
Transcat, Inc. Q1 FY2027 Earnings Call - Service Revenue Hits 69th Consecutive Quarter of Growth as New CEO Bets on Operational Excellence
Transcat delivered another quarter of relentless top-line expansion, with consolidated revenue jumping 22% to $92.9 million and service revenue climbing 27%. The 69th straight year-over-year service g...
- Consolidated revenue increased 22% year-over-year to $92.9 million, driven by double-digit growth across both service and distribution segments.
- Service revenue surged 27%, with 13% organic growth marking the company’s 69th consecutive quarter of year-over-year service revenue expansion.
- Service gross profit climbed 31%, with service adjusted operating margins expanding 90 basis points to 15.4%, reflecting inherent operating leverage and maturing customer relationships.
- +8 more takeaways
"Unitil Corporation" Q2 2026 Earnings Call - H1 Earnings Up 7% as Water Acquisition Closes and Gas Conversion Demand Surges
Unitil delivered a disciplined first half of 2026, posting adjusted earnings of $2.17 per share, a nearly 7% improvement over the prior year. The utility is fully earning its authorized returns, ancho...
- First-half adjusted net income reached $39 million, or $2.17 per share, marking a nearly 7% year-over-year increase while the company fully earns its authorized returns with a 9.6% trailing GAAP return on equity.
- Management reaffirmed 2026 adjusted earnings guidance of $3.20 to $3.36 per share and maintained its long-term earnings growth target of 5% to 7%.
- The $55.8 million acquisition of the Aquarion Water Company of New Hampshire and Abenaki Water Company closed on June 30, adding regulated scale and expected to transition from earnings neutral to accretive once new distribution rates take effect.
- +7 more takeaways
"Ecopetrol" Q2 2026 Earnings Call - Record Refining Margins and H1 Profit Surge Offset Production Headwinds
Ecopetrol’s second quarter of 2026 reads like a masterclass in margin capture. Brent crude averaging $88 per barrel and a record-breaking 439,000 barrels per day at the refinery turned a volatile year...
- First-half net income reached COP 9 trillion, matching full-year 2025 results, driven by Brent averaging $88 per barrel and record refining margins.
- Integrated refining throughput hit a historical high of 439,000 barrels per day, pushing gross margins to $29.80 per barrel, nearly doubling year-over-year performance.
- A 76-day blockade in Meta and grid disruptions temporarily shaved 23,000 barrels per day off output, but management maintains the 730,000 to 740,000 bpd full-year guidance.
- +7 more takeaways
"Sabra Health Care REIT" Q2 2026 Earnings Call - Leverage Drops to 4.61x as SHOP Momentum and Avamere Rent Step-Ups Fuel Upgraded 2026 Guidance
Sabra Health Care REIT is executing with disciplined precision as capital markets remain stubbornly fragmented. The second quarter delivered a clear demonstration of operational leverage, with managed...
- Sabra closed roughly $600 million in investments during Q2, bringing year-to-date deal flow to nearly $600 million with an estimated initial cash yield of 7.5 percent.
- Managed senior housing revenue surged 9.6 percent sequentially, while cash NOI jumped 14.4 percent, driven by occupancy gains and margin expansion across the same-store portfolio.
- Same-store occupancy climbed 170 basis points to 88.2 percent, with RevPAR rising 6.6 percent year-over-year, signaling sustained pricing power and demand strength.
- +7 more takeaways